Pharma: Page 17
-
Daniel Tadevosyan via Getty Images
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
By BioPharma Dive staff • June 7, 2024 -
Dr_Microbe via Getty Images
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
An advisory panel is meeting today to discuss whether donanemab is effective across different groups of Alzheimer's patients, and to give input on an unusual dosing strategy used by Lilly.
By Jonathan Gardner • June 6, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Courtesy of Seres Therapeutics
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
Seres did not disclose financial details for the deal, but said it would help extend the company's cash runway by one year.
By Kristin Jensen • June 6, 2024 -
Daniel Tadevosyan via Getty Images
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.
By BioPharma Dive staff • June 5, 2024 -
Scott Olson via Getty Images
Lilly CFO leaves to join Alphabet
Anat Ashkenazi is switching industries after a 23-year career at the Indianapolis drugmaker.
By Kristin Jensen • June 5, 2024 -
Alyssa Eckel-Martin/BioPharma Dive
Sponsored by BioLineRx[Podcast] The Power of Persistence: From Biotech Incubator to Product Launch
How can small and mid-sized biotech companies better manage pharmacovigilance during clinical trials? Listen to the podcast to learn how strategic alliances are helping.
By BioPharma Dive's studioID • Updated June 18, 2024 -
JHVEPhoto via Getty Images
ALS drug developmentEli Lilly adds ALS drug prospect with QurAlis deal
The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.
By Gwendolyn Wu • June 3, 2024 -
Riska via Getty Images
Sponsored by VMS BioMarketingOral cancer medications: The adherence paradox
The number of oral cancer medications is increasing, opening new possibilities for improved convenience, but some studies show much lower adherence rates with oral oncolytics.
By Abigail Mallon, Chief Patient Experience Officer, VMS BioMarketing • June 3, 2024 -
Image Source via Getty Images
Sponsored by SmartLabsThinking inside the box: How SmartLabs is supporting the science of tomorrow
With new modalities such as gene and cell therapies, RNA therapeutics, complex biologics and more, today’s science brings unprecedented opportunities to address diseases that have long remained out of reach.
June 3, 2024 -
ASCO / Nick Agro
GSK builds case for return of multiple myeloma drug Blenrep
Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.
By Jonathan Gardner • June 2, 2024 -
Jonathan Gardner/BioPharma Dive
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
The findings, from a trial testing Imfinzi in limited-stage small cell lung cancer, could help AstraZeneca expand the drug's use.
By Jonathan Gardner • Updated June 2, 2024 -
Daniel Tadevosyan via Getty Images
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.
By BioPharma Dive staff • May 31, 2024 -
Permission granted by Otsuka Precision Health
Otsuka defies digital health downturn with new company
With “no playbook out there” to fall back on, the new company is taking a long-term approach as it develops its portfolio, an Otsuka Precision Health exec told MedTech Dive.
By Elise Reuter • May 30, 2024 -
Mario Tama via Getty Images
J&J antidepressant eases symptoms, improves sleep in key trial
The company has put high expectations on the drug, an orexin-2 antagonist called seltorexant, as a cornerstone of its neuropsychiatry pipeline.
By Ned Pagliarulo • May 29, 2024 -
Getty Images via Getty Images
Can robots break the cell therapy bottleneck?
A partnership between cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could address manufacturing hurdles, the CEOs said.
By Michael Gibney • May 29, 2024 -
Mario Tama via Getty Images
J&J gains another bispecific antibody with $1.25B skin drug buy
The deal is J&J’s second this month involving bispecific antibodies, which the company has prioritized to build its immune and cancer drug pipeline.
By Ben Fidler • May 28, 2024 -
Daniel Tadevosyan via Getty Images
Roche’s Sabry retires; Duchenne drug fails confirmatory test
The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative Phase 3 data and Merck unveiled new breast cancer results for Keytruda.
By BioPharma Dive staff • May 28, 2024 -
Marco VDM via Getty Images
Sponsored by CognizantThe future of medicine: AI’s role in uncovering new drugs
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges.
May 28, 2024 -
Michael M. Santiago via Getty Images
Pfizer expands cost cuts with new $1.5B target
The company, which previously announced plans to trim $4 billion in spending by the end of 2024, aims to save another $1.5 billion over the next three years.
By Ned Pagliarulo • May 22, 2024 -
Daniel Tadevosyan via Getty Images
Regeneron faces new biosimilar threats; an AI biotech lays off staff
Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers.
By BioPharma Dive staff • May 22, 2024 -
Christopher Furlong via Getty Images
AstraZeneca’s $80B sales plan leans on cancer drug expansion
The drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.
By Jonathan Gardner • May 21, 2024 -
AstraZeneca sets sights on $80B in revenue by 2030
The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.
By Jonathan Gardner • May 21, 2024 -
Daniel Tadevosyan via Getty Images
Erasca restructures; Novartis moves to complete MorphoSys deal
The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.
By BioPharma Dive staff • May 17, 2024 -
Courtesy of Roche
Roche keeps pace in obesity drug field with early study data
A drug Roche acquired in a buyout of Carmot Therapeutics and that works similarly to Zepbound helped people lose nearly 19% of their body weight in a Phase 1 trial.
By Jonathan Gardner • May 16, 2024 -
Mario Tama via Getty Images
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.
By Kristin Jensen • May 16, 2024
Previous
